[Angiotensin receptor blockers--significance for the therapy of hypertension]

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Angiotensin receptor antagonists (ARBs) offer comparable efficacy to other antihypertensives with improved tolerability.
• Higher acquisition costs currently limit their first-line use in uncomplicated hypertension.
• The economic balance may shift favorably with reduced therapy monitoring requirements.

Purpose of the Study:

• To evaluate the comparative cost-effectiveness of ARBs versus other antihypertensive agents.
• To explore the potential benefits of ARBs in associated cardiovascular and renal conditions.
• To assess the impact of ARB tolerability on patient adherence and healthcare resource utilization.

Main Methods:

• Analysis of clinical trial data and cost-effectiveness models.
• Review of evidence for ARB efficacy in hypertension and related comorbidities.
• Examination of factors influencing treatment adherence and monitoring frequency.

Main Results:

• ARBs demonstrate significant potential in managing cardiac failure, left ventricular hypertrophy, and nephropathy.
• Improved patient adherence due to fewer side effects is a key advantage.
• Reduced need for frequent safety controls can positively impact overall treatment costs.

Conclusions:

• ARBs represent a highly effective and tolerable treatment option for a significant proportion of hypertensive patients.
• Their favorable side-effect profile enhances adherence and potentially reduces long-term healthcare costs.
• Further economic analyses are warranted to fully elucidate the cost-effectiveness of ARBs in diverse clinical scenarios.